SCHEMBL38147046

SCHEMBL38147046

Cc1ccc2ccc(C(=O)N[C@H](C(=O)O)C(C)(C)C)c(OCc3ccc(C(F)(F)F)cc3)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 1/20 0.51
▸ MME P08473 1/20 0.39
▸ ACE P12821 1/20 0.39
▸ CPA1 P15085 1/20 0.39
▸ ACE2 Q9BYF1 1/20 0.39
▸ PPARA Q07869 6/20 0.37
▸ ADAMTS4 O75173 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ KIFC1 Q9BW19 1/20 0.37
▸ CTNNB1 P35222 1/20 0.37
▸ TCF7L2 Q9NQB0 1/20 0.37
▸ PPARD Q03181 3/20 0.36
▸ PYGL P06737 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ PLG P00747 1/20 0.36
▸ KLK1 P06870 1/20 0.36
▸ MAOB P27338 3/20 0.36
▸ SORT1 Q99523 1/20 0.36
▸ PSEN1 P49768 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460990 1.00 CXCR2 (0.51) CXCR2MMEACECPA1ACE2
SCHEMBL23462250 1.00 CXCR2 (0.51) CXCR2MMEACECPA1ACE2
SCHEMBL23460988 1.00 CXCR2 (0.51) CXCR2MMEACECPA1ACE2
SCHEMBL23460950 0.94 CXCR2 (0.50) CXCR2MMEACECPA1ACE2
SCHEMBL38147123 0.94 CXCR2 (0.50) CXCR2MMEACECPA1ACE2
SCHEMBL23460953 0.94 CXCR2 (0.50) CXCR2MMEACECPA1ACE2
SCHEMBL23460739 0.93 CXCR2 (0.53) CXCR2MMEACECPA1ACE2
SCHEMBL23460741 0.93 CXCR2 (0.53) CXCR2MMEACECPA1ACE2
SCHEMBL23461034 0.93 CXCR2 (0.53) CXCR2MMEACECPA1ACE2
SCHEMBL23460861 0.93 CXCR2 (0.54) CXCR2MMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885MME 2964/4885ACE 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback